Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa–Levodopa
Aravind Mittur, Suneel Gupta, Nishit B. Modi
Clinical Pharmacokinetics (2017) Vol. 56, Iss. 9, pp. 999-1014
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Levodopa-loaded nanoparticles for the treatment of Parkinson's disease
Emile F. van Vliet, Maarten J. Knol, Raymond M. Schiffelers, et al.
Journal of Controlled Release (2023) Vol. 360, pp. 212-224
Open Access | Times Cited: 29
The Roles of Neuroinflammation in l‐DOPA‐Induced Dyskinesia: Dissecting the Roles of NF‐κB and TNF‐α for Novel Pharmacological Therapeutic Approaches
Mohammad Yasin Zamanian, Maryam Golmohammadi, Zhanna R. Gardanova, et al.
European Journal of Neuroscience (2025) Vol. 61, Iss. 5
Open Access | Times Cited: 1
Contributions of Gut Bacteria and Diet to Drug Pharmacokinetics in the Treatment of Parkinson's Disease
Sebastiaan P. van Kessel, Sahar El Aidy
Frontiers in Neurology (2019) Vol. 10
Open Access | Times Cited: 43
Increased foot strike variability in Parkinson's disease patients with freezing of gait
Jesal Shah, Lakshmi Pillai, D. Keith Williams, et al.
Parkinsonism & Related Disorders (2018) Vol. 53, pp. 58-63
Open Access | Times Cited: 46
James Parkinson and Other Historical Aspects of Parkinson’s Disease
Helen L. Dainton-Howard, Christopher G. Goetz
Neurologic Clinics (2025)
Closed Access
Rethinking the Role of Continuous Dopaminergic Stimulation in Parkinson Disease Therapy
Peter A. LeWitt
Parkinsonism & Related Disorders (2025), pp. 107354-107354
Closed Access
20-Week Toxicity Study of Rotigotine Behenate Extended-Release Microspheres for Intramuscular Injection in Sprague Dawley Rats
Wenjing Lv, Hong Zhang, Yumeng Chen, et al.
Food and Chemical Toxicology (2025), pp. 115384-115384
Closed Access
From Lab-to-Clinic with Model Informed Formulation Development: A Case Study of Hydroxyzine SR Tablets
Aditya Murthy, Shubham Jamdade, Manoj Gundeti, et al.
Xenobiotica (2025), pp. 1-16
Closed Access
One-step fabrication of bicompartmental microparticles as a dual drug delivery system for Parkinson’s disease management
Ashok Kr. Parthipan, N.M. Gupta, Kalpana Pandey, et al.
Journal of Materials Science (2018) Vol. 54, Iss. 1, pp. 730-744
Closed Access | Times Cited: 38
Contemporary Options for the Management of Motor Complications in Parkinson’s Disease: Updated Clinical Review
Verónica Cabreira, Patrício Soares‐da‐Silva, João Massano
Drugs (2019) Vol. 79, Iss. 6, pp. 593-608
Closed Access | Times Cited: 33
Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson’s Disease
Nirosen Vijiaratnam, Thomas Foltynie
Drugs (2020) Vol. 80, Iss. 8, pp. 775-796
Closed Access | Times Cited: 29
Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice
Alberto Corsini, Nicola Ferri, Marco Proietti, et al.
Drugs (2020) Vol. 80, Iss. 11, pp. 1065-1083
Closed Access | Times Cited: 29
Crystal Structures of Cystathionine β-Synthase from Saccharomyces cerevisiae: One Enzymatic Step at a Time
Yupeng Tu, C.A. Kreinbring, Megan Hill, et al.
Biochemistry (2018) Vol. 57, Iss. 22, pp. 3134-3145
Open Access | Times Cited: 27
Development, Optimization, and Evaluation In Vitro/In Vivo of Oral Liquid System for Synchronized Sustained Release of Levodopa/Benserazide
Yang Qu, Wenlong Lai, Yuanrong Xin, et al.
AAPS PharmSciTech (2019) Vol. 20, Iss. 8
Closed Access | Times Cited: 23
Optimizing Patient-Specific Medication Regimen Policies Using Wearable Sensors in Parkinson’s Disease
Matt Baucum, Anahita Khojandi, Rama K. Vasudevan, et al.
Management Science (2023) Vol. 69, Iss. 10, pp. 5964-5982
Open Access | Times Cited: 7
Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation
Peter A. LeWitt, Aaron Ellenbogen, Daniel Burdick, et al.
Clinical Parkinsonism & Related Disorders (2023) Vol. 8, pp. 100197-100197
Open Access | Times Cited: 7
Gait Declines Differentially in, and Improves Prediction of, People with Parkinson’s Disease Converting to a Freezing of Gait Phenotype
Tuhin Virmani, Reid D. Landes, Lakshmi Pillai, et al.
Journal of Parkinson s Disease (2023) Vol. 13, Iss. 6, pp. 961-973
Open Access | Times Cited: 7
Long-term management of Parkinson’s disease using levodopa combinations
Thomas Müller, Jan-Dominique Möhr
Expert Opinion on Pharmacotherapy (2018) Vol. 19, Iss. 9, pp. 1003-1011
Closed Access | Times Cited: 21
Study on the Role of the Inclusion Complexes with 2-Hydroxypropyl-β-cyclodextrin for Oral Administration of Amiodarone
Andreea Crețeanu, Daniela Pamfil, Cornelia Vasile, et al.
International Journal of Polymer Science (2019) Vol. 2019, pp. 1-23
Open Access | Times Cited: 21
Levodopa ONOFF-state freezing of gait: Defining the gait and non-motor phenotype
Reid D. Landes, Aliyah Glover, Lakshmi Pillai, et al.
PLoS ONE (2022) Vol. 17, Iss. 6, pp. e0269227-e0269227
Open Access | Times Cited: 12
Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson’s disease
Abhishek Lenka, Gianluca Di Maria, Guillaume Lamotte, et al.
Expert Review of Neurotherapeutics (2022) Vol. 22, Iss. 6, pp. 489-498
Closed Access | Times Cited: 12
Extended-release oral capsule of carbidopa–levodopa in Parkinson disease
Jason Margolesky, Carlos Singer
Therapeutic Advances in Neurological Disorders (2017) Vol. 11
Open Access | Times Cited: 21
Efficacy of carbidopa-levodopa extended-release capsules (IPX066) in the treatment of Parkinson Disease
Thomas Müller, Jan-Dominique Möhr
Expert Opinion on Pharmacotherapy (2018) Vol. 19, Iss. 18, pp. 2063-2071
Closed Access | Times Cited: 18
Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
Robert A. Hauser, Aaron Ellenbogen, Sarita Khanna, et al.
Neuropsychiatric Disease and Treatment (2018) Vol. Volume 14, pp. 839-845
Open Access | Times Cited: 17
A Review of Levodopa Formulations for the Treatment of Parkinson’s Disease Available in the United States
Clare Livingston, Laura Monroe-Duprey
Journal of Pharmacy Practice (2023) Vol. 37, Iss. 2, pp. 485-494
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top